Over the course of his career, Dr. Mark Paskewitz has contributed to the development of several innovative pharmaceuticals. He served for four years as director and later senior director of clinical development for Kyowa Hakko Kirin Pharma, a global pharmaceutical company. Dr. Mark Paskewitz played a key role in the company's development of burosumab, a drug recently approved in Europe and the US for the treatment of a genetic bone disease known as X-Linked Hypophosphatemia (XLH).

Dr. Mark Paskewitz played a critical role in clinical research planning for the drug, which has become the first of its kind to treat its target condition. He also contributed significantly to the preparation of regulatory approval submissions and coordinated efforts of a diverse team of professionals, including scientific advisors and researchers, as well as vendors and data-safety monitors.

Dr. Paskewitz now serves as vice president of clinical operations for the National Institute of Clinical Research. Effective at introducing a management system based on metrics, he has enabled the company to more effectively evaluate project outcomes and team results. He focuses the company's attention on the renal-care field, while also contributing to studies in oncology and cardiology.